Skip to main content

A brand new analysis paper was revealed in Oncotarget’s Quantity 15 on March 14, 2024, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.”

ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML therapy. Its efficacy in hematopoietic stem cell transplantation (HSCT), when mixed with different chemotherapeutic medicine, has not been completely investigated. On this new research, researchers Benigno C. Valdez, Bin Yuan, David Murray, Jeremy L. Ramdial, Uday Popat, Yago Nieto, and Borje S. Andersson from The College of Texas MD Anderson Most cancers Middle and the College of Alberta display the synergistic cytotoxicity of ABT199/venetoclax with the DNA alkylator thiotepa (Thio) in AML cells. 

“The outcomes might present related info for the design of medical trials utilizing these medicine to avoid acknowledged drug-resistance mechanisms when used as a part of pre-transplant conditioning regimens for AML sufferers present process allogenic HSCT.”

Cleavage of Caspase 3, PARP1 and HSP90, in addition to elevated Annexin V positivity, counsel potent activation of apoptosis by this two-drug mixture; elevated ranges of γ-H2AX, P-CHK1 (S317), P-CHK2 (S19) and P-SMC1 (S957) point out an enhanced DNA harm response. Likewise, the elevated stage of P-SAPK/JNK (T183/Y185) and decreased P-PI3Kp85 (Y458) counsel enhanced activation of stress signaling pathways. These molecular readouts have been synergistically enhanced when ABT199/venetoclax and Thio have been mixed with fludarabine, cladribine and busulfan. 

The five-drug mixture decreased the degrees of BCL-2, BCL-xL and MCL-1, suggesting its potential medical relevance in overcoming ABT199/venetoclax resistance. Furthermore, this mix is lively towards P53-negative and FLT3-ITD-positive cell traces. Enhanced activation of apoptosis was noticed in leukemia patient-derived cell samples uncovered to the five-drug mixture, suggesting a medical relevance. 

“The outcomes present a rationale for medical trials utilizing these two- and five-drug combos as a part of a conditioning routine for AML sufferers present process HSCT.”

Supply:

Journal reference:

Valdez, B. C., et al. (2024). ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget. doi.org/10.18632/oncotarget.28563.


Supply hyperlink

Hector Antonio Guzman German

Graduado de Doctor en medicina en la universidad Autónoma de Santo Domingo en el año 2004. Luego emigró a la República Federal de Alemania, dónde se ha formado en medicina interna, cardiologia, Emergenciologia, medicina de buceo y cuidados intensivos.

Leave a Reply